A study led by biomedical scientists at the University of California, Riverside School of Medicine shows how a genetic ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the ...

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

US FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell disease: Paris Thursday, June 5, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ( ...

Zenas BioPharma has released its corporate presentation for June 2025, providing an insight into its financial and clinical ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of historical and ...

Sanofi announced today that the U.S. FDA has granted orphan drug designation to rilzabrutinib for the treatment of sickle ...

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.